HomeBody MapPeptidesCalculator
Catalog11 refs

FOXO4-DRI

Longevity & MitochondrialLongevity & Cellular HealththerapeuticSenolytic PeptideLongevity & SenolyticAnti-AgingResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Not Well Characterized In Humans
Half-life
40
Uses
~25 mg
Typical
Body Map
Loading 3D model…
CirculationJointsSkin
Overview

FOXO4-DRI is a D-retro-inverso senolytic peptide designed to selectively eliminate senescent 'zombie' cells that accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, causing p53 to be excluded from the nucleus and triggering apoptosis. The DRI modification uses reversed D-amino acids to increase potency and stability. Preclinical research shows restoration of fur density, fitness, and organ function in aged mice.

Primary Uses
Selective elimination of senescent cells
Tissue rejuvenation and anti-aging
Restoring fur density in aged mice
Improving kidney function markers
Increasing voluntary running and fitness in fast-aging mice
Protecting against chemotherapy side effects including liver damage and weight loss
Clearing damaged cells from Leydig cells to improve testosterone production
Improving sperm quality by reducing inflammatory signals in testes
Reducing lung scarring (fibrosis) and excess collagen buildup
Clearing damaged cells from lung tissue and lowering inflammatory signaling
Reducing age-related damage to blood vessel lining and improving vascular function
Selective clearance of senescent cells (senolysis)
Anti-aging research
Restoring tissue homeostasis in response to chemotoxicity and aging
Longevity research comparing senolytics
Senolytic research
Cellular senescence clearance
Aging-biomarker studies
Tissue rejuvenation models
Keloid senescent fibroblast apoptosis
Spermatogenesis improvement in aged models
Age-related testosterone secretion insufficiency
Endothelial cell senescence regulation
Chondrocyte senescent cell removal
Tissue rejuvenation and restoration of tissue homeostasis
Improved fitness and physical function in aged models
Restored fur density in aged mice
Improved kidney function
Alleviates chemotherapy-induced senescence
Restores testosterone in aged males
Reduces senescent chondrocytes in cartilage
Chemotherapy recovery (neutralizes doxorubicin-induced chemotoxicity)
Senescent cell elimination
Senolytic activity
Age-related disease treatment
Killing senescent cells (senolytic)
Restoring fur density
Restoring kidney function
Restoring physical fitness
Counteracting doxorubicin toxicity
Protocol Reference
Dose
~25 mg per injection
Frequency
Every Other Day X 3 Doses Per Cycle (days 1, 3, 5)
Half-life
Not Well Characterized In Humans
Route
Subcutaneous
Evidence
Preclinical / Preclinical (mouse studies only, no human safety data) / Emerging (disputed)
Research References· 17
Morphological changes in the liver of experimental animals with combined introduction of adribastin and FOXO4-DRI↗
DOI.216-222)
Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging
PubMedPMID 28340339. Cell, 2017.
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway↗
DOIFrontiers in Bioengineering and Biotechnology2026Hu Z, Li F, Hu C, et al.
Research Models
HumanMousehuman (in vitro chondrocytes)human (in vitro)
Also in Longevity & Mitochondrial
Longevity & Mitochondrial
BAM-15
Obesity/Fat Loss · Insulin Resistance
Longevity & Mitochondrial
Epitalon
anti-aging · telomere maintenance
Longevity & Mitochondrial
Epithalon
Activating telomerase · Supporting pineal gland function
Longevity & Mitochondrial
Humanin
Brain protection from amyloid-beta toxicity · Metabolic regulation
Compare